The latest price target for Travere Therapeutics (NASDAQ:TVTX) was reported by JP Morgan on September 13, 2024. The analyst firm set a price target for $23.00 expecting TVTX to rise to within 12 months (a possible 50.72% upside). 33 analyst firms have reported ratings in the last year.

The latest analyst rating for Travere Therapeutics (NASDAQ:TVTX) was provided by JP Morgan, and Travere Therapeutics maintained their overweight rating.

The last upgrade for Travere Therapeutics Inc happened on September 9, 2024 when Guggenheim raised their price target to $25. Guggenheim previously had a neutral for Travere Therapeutics Inc.

The last downgrade for Travere Therapeutics Inc happened on March 27, 2024 when Guggenheim changed their price target from N/A to N/A for Travere Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on September 13, 2024 so you should expect the next rating to be made available sometime around September 13, 2025.

While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a maintained with a price target of $20.00 to $23.00. The current price Travere Therapeutics (TVTX) is trading at is $15.26, which is out of the analyst’s predicted range.